94937-86-7

Usage

Uses

Used in Pharmaceutical Research:
2-Chloromethyl-1-phenyl-1H-benzoimidazole is utilized as a potential drug candidate for the treatment of various medical conditions due to its unique chemical and biological properties. Its structure allows for the exploration of its potential in treating a range of disorders, including cancer and infectious diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE serves as a promising candidate for further exploration and study. Its chemical properties and biological activities make it a valuable subject for the development of new therapeutic agents, with the aim of enhancing treatment options for various diseases.
Used in Drug Development:
2-CHLOROMETHYL-1-PHENYL-1H-BENZOIMIDAZOLE's potential applications in the treatment of cancer, infectious diseases, and other disorders make it a significant player in drug development. Its unique structure and properties are being investigated to identify ways to optimize its therapeutic effects and minimize potential side effects, ultimately contributing to the advancement of novel pharmaceuticals.

InChI:InChI=1S/C14H11ClN2/c15-10-14-16-12-8-4-5-9-13(12)17(14)11-6-2-1-3-7-11/h1-9H,10H2

Upstream product

• 4857-04-9 2-chloromethyl-1H-benzimidazole 
• 98-80-6 phenylboronic acid 
• 1493-27-2 ortho-nitrofluorobenzene 
• 62-53-3 aniline 
• 79-04-9 chloroacetyl chloride 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 119-75-5 2-nitro-N-phenylaniline 
• 94937-85-6 2-chloro-N-[2-(phenylamino)phenyl]-acetamide 

Downstream Products

• 1393180-75-0 7-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1393180-98-7 4-chloro-1-(1-phenyl-1H-benzoimidazol-2-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-6-ylamine 
• 1393180-79-4 3-iodo-1-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1393180-42-1 9-((1-phenyl-1H-benzo[d]imidazol-2-yl)methyl)-9H-purin-6-amine 
• 94937-93-6 2-(1H-1,2,4-triazol-1-yl)methyl-1-phenyl-1H-benzimidazole 

Relevant academic research and scientific papers

Imidazo[4,5-c]pyridine derivative and application thereof

The invention relates to a novel imidazo[4,5-c]pyridine derivative represented by a general formula I, and pharmaceutically acceptable salts, solvates or prodrugs of the novel imidazo[4,5-c]pyridine derivative, wherein the substituent R and R' are defined as in the specification. The invention also relates to an effect of the compound represented by the general formula I in inhibiting an NS5B RNA-dependent RNA polymerase (NS5B polymerase for short) which is necessary in a replication process of hepatitis c virus, also relates to an application of the compound, and pharmaceutically acceptable salts, hydrates or prodrugs of the compound in preparation of medicines for treating viral diseases, and especially relates to an application in preparation of medicines for treating and/or preventinghepatitis c.

N, O-Bidentate ligand-tunable copper(II) complexes as a catalyst for Chan-Lam coupling reactions of arylboronic acids with 1 H-imidazole derivatives

An efficient procedure for Chan-Lam coupling reactions of arylboronic acids with 1H-imidazole derivatives using N,O-bidentate ligand-tunable copper(ii) complexes as a catalyst under base-free conditions has been developed. This protocol features mild reac

Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B

The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163 nM and a CC50 >200 nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase.

Antiulcer fused imidazole compounds

New fused imidazole compounds of the formula: STR1 wherein A is lower alkylene, R1 is hydrogen, lower alkyl, lower alkoxy or halogen, R2 is hydrogen, lower alkyl, cyclo(lower)alkyl, pyridyl, ar(lower)alkyl which may be substituted wi